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Recent advances in diabetes technology have led to the development of closed-loop
insulin delivery systems for the management of type 1 diabetes. Several such systems
are now commercially available for children and young people. While all available systems
have been shown to improve glycaemic control and quality of life in this population,
qualitative data also highlights the challenges in using closed-loop systems, which vary
among different pediatric age-groups. Very young children require systems that are able
to cope with low insulin doses and significant glycaemic variability due to their high insulin
sensitivity and unpredictable eating and exercise patterns. Adolescents’ compliance is
often related to size and number of devices, usability of the systems, need for calibrations,
and their ability to interact with the system. Given the speed of innovations, understanding
the capabilities and key similarities and differences of current systems can be challenging
for healthcare professionals, caregivers and young people with type 1 diabetes alike. The
aim of this review is to summarize the key evidence on currently available closed-loop
systems for children and young people with type 1 diabetes, as well as commenting
on user experience, where real-world data are available. We present findings on a
system-basis, as well as identifying specific challenges in different pediatric age-groups
and commenting on how current systems might address these. Finally, we identify areas
for future research with regards to closed-loop technology tailored for pediatric use and
how these might inform reimbursement and alleviate disease burden.
Keywords: diabetes technology, young people, type 1 diabetes (or diabetes), closed-loop insulin delivery, artificial
pancreas (AP), children
Type 1 diabetes is a lifelong, incurable condition characterized by a deficiency of insulin caused by
immune-mediated destruction of pancreatic beta-cells in genetically predisposed individuals (1).
Its incidence in the pediatric population is increasing by around 3% per year (2), and more than
one million children and young people under the age of 20 years are living with the condition
worldwide (3). Tight glycaemic control is challenging to achieve, and the majority of children and
young people with type 1 diabetes do not meet treatment guidelines for target glycated hemoglobin
(HbA1c) (4–7), or only achieve good glycaemic control at the expense of high management burden
(8–10). Meeting glycaemic targets is vital, as higher HbA1c levels are associated with an increased
risk of premature morbidity and mortality (11–13).
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Over the past decades, several new technologies have been
developed to improve management of type 1 diabetes, including
insulin pumps and real-time continuous glucose monitoring
(CGM) devices (14). However, rather than improving, HbA1c
levels have worsened in the pediatric age group over the last
10 years (5). While insulin pumps and CGM devices have been
shown to lower HbA1c levels and reduce the risk of diabetic
ketoacidosis (15–17), they require significant user-input and
frequent insulin dosing adjustments to achieve good glycaemic
control (10). In recent years, the development of closed-loop
systems, which link insulin delivery to sensor glucose levels, have
started to transform management of type 1 diabetes (18, 19).
These closed-loop systems utilize an algorithm that automatically
adjusts insulin delivery via an insulin pump based on real-time
sensor glucose levels. This glucose-responsive automated insulin
delivery more closely replicates normal physiology. Current
hybrid closed-loop systems continue to require user-initiated
prandial insulin boluses.
This review summarizes key evidence on current closed-loop
systems for children and young people with type 1 diabetes, as
well as commenting on user experience and specific challenges in
different pediatric age-groups.
CLOSED-LOOP SYSTEMS
Four hybrid closed-loop systems are currently commercially
available and licensed for use in children and young people, with
varying minimum age for use. These systems are: 670G hybrid
closed-loop (HCL) system and 780G advanced HCL (AHCL)
(Medtronic, Northridge, California); CamAPS FX interoperable
app (CamDiab, Cambridge, UK); and the Control IQ system
(Tandem Inc., San Diego, California). Further hybrid closed-
loop systems are in development, with pivotal trials under
way (20). Table 1 summarizes the key clinical trial evidence of
commercialized systems in children and young people.
The closed-loop algorithm is embedded in the software
of the tethered insulin pump and communicates wirelessly
with the compatible glucose sensor for the Medtronic and
Tandem systems (14). For CamAPS FX, the algorithm is
embedded in an app, classed as a medical device, residing
on an unlocked smartphone that communicates wirelessly
with a compatible insulin pump and glucose sensor (14).
As more hybrid closed-loop systems become commercially
available, it is becoming increasingly complex for people with
type 1 diabetes, their families and healthcare professionals
to navigate different technologies. While similar in basic
principle, there are important differences between each
hybrid closed-loop system, and clinicians need to understand
key device characteristics in order to provide appropriate
clinical support and guidance to children, young people and
their families. Several available closed-loop systems now
provide online training and education modules, both for
healthcare professionals and users, and increasingly module
completion is a requirement to allow initiation of closed-
loop. Table 2 outlines the capabilities and key similarities and
differences of current systems using the CARES paradigm,
an educational tool developed by Messer et al. (32), that
provides a practical framework to identify key concepts for
each closed-loop system. Understanding these key concepts will
allow healthcare professionals to set appropriate expectations
of hybrid closed-loop system capabilities, and to adjust settings
for treatment optimisation to maximize the benefits of this
novel therapy.
Clinical trials show that hybrid closed-loop insulin delivery is
safe and improves glycaemic outcomes in children of all ages (10,
33), but high quality real-world data remains scarce, particularly
for newer systems licensed in the last 12–18 months. Considering
the evidence available in terms of system capabilities, qualitative
research and observational real-world data, we discuss age-
specific challenges in children and young people and how closed-
loop systems might address these.
TODDLERS AND YOUNG CHILDREN
Type 1 diabetes is challenging to manage at any age,
but management is further complicated in young children
under the age of 7 by a variety of unique physiological,
behavioral and developmental factors. Young children have
higher variability in insulin requirements and higher insulin
sensitivity than older children and adults (34), as well as
more unpredictable eating and activity patterns. Furthermore,
hypoglycaemia is frequently asymptomatic and can be prolonged,
particularly at night-time (35, 36). These factors and resulting
parental worry lead to high management burden for parents
and caregivers with negative impact on family quality of
life (9).
Closed-loop studies in this age-group have been of short
duration in small cohorts (Table 1). One of the main benefits
of hybrid closed-loop insulin delivery in young children is
improved glycaemic control at night-time. In a 3-week closed-
loop study in 24 very young children, time in the target
range 3.9–10.0 mmol/L was highest overnight with reduction in
hypoglycaemia compared to daytime (31) (Table 1). Variability
in insulin requirements in young children is highest overnight
(34), and closed-loop systems are uniquely positioned to address
this by delivering insulin in a glucose-responsive manner.
Qualitative data shows that parents noted improvements in
quality of sleep with closed-loop, both for themselves and their
child (37, 38).
Improvements in glycaemic control are less marked in
the daytime, which is likely related to unpredictable eating
and activity patterns. Bolus timing is challenging in this
age group, as children frequently graze or do not complete
meals. Many parents choose to bolus with or shortly after
the start of the meal, leading to post-prandial hyperglycaemia
(39, 40). The pharmacokinetics and pharmacodynamics of
current rapid-acting insulins limit the closed-loop system’s
ability to mitigate immediate post-prandial hyperglycaemia
(41), and the resultant increase in algorithm-driven insulin
delivery increases the risk of delayed hypoglycaemia. New
ultra-rapid acting insulins, which have faster onset and offset
of action, have the potential to address this issue, but
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2018 (31)
HCL, hybrid closed-loop; AHCL, advanced hybrid closed-loop; PLGM, predictive low glucose management; TIR, time in range; HbA1c, glycated hemoglobin.
these have not been trialed in closed-loop systems in the
pediatric age-group.
Another limitation of current closed-loop systems is the
minimum total daily insulin dose required for optimal system
performance. While this does not preclude use in those young
children with a very low total daily dose, it can limit the benefit of
closed-loop therapy due to the high variability of absorption with
such small volumes (42). A randomized trial comparing closed-
loop insulin delivery using diluted and standard strength insulin
showed no difference in glycaemic outcomes between the two
groups (31). However, only a small number of participants had
a total daily insulin dose of <10 units in this cohort. Previous
shorter closed-loop studies using diluted insulin in this age
group showed reduced inter-individual variability in time to peak
insulin action with diluted insulin (42), suggesting that insulin
dilution may be beneficial on a case-by-case basis in those with a
very low total daily insulin dose.
In spite of these limitations, qualitative studies reported
parents spending less time performing diabetes-related activities
and feeling less stressed when their child was using closed-loop,
resulting in reduced management burden overall (37, 38).
There is limited real-world closed-loop data available for very
young children. This is in part due to the fact that closed-
loop insulin delivery is only licensed for one commercialized
system (CamAPS FX) in this age group, with other systems
being used off-license in some centers. A retrospective case
series of the 670G HCL system in 16 children under the
age of 7 years showed improvements in glycaemic control
compared to baseline (43). There was an increase in time
in hypoglycaemia, however this was still low at 2.4% (43).
Importantly, the results of further clinical closed-loop trials in
very young children are expected to be reported in the near
future, and should result in licensing of a wider variety of systems
in this age group.
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TABLE 2 | Comparison of commercially available closed-loop systems using the CARES paradigm (32).
CARES 670G/780G Control IQ CamAPS FX
Licensing 7 years+ 6 years+ 1 year+
Availability USA and Europe USA & Europe Europe
Pump Medtronic 670G / 780G Tandem t:slim X2 Dana RS, Dana-i
Insulin Rapid-acting Rapid-acting Ultra-rapid and rapid-acting







Algorithm Treat-to-target proportional integral
derivative with insulin feedback
(670G); added fuzzy logic component
(780G)
Treat-to-range predictive control Treat-to-target MPC
Set-up TDD, weight, basal rates, ICR, ISF,
active insulin time.
7 days of manual mode
TDD, weight, basal rates, ICR, ISF TDD and weight
Adaptive learning Overall Not specified by manufacturer Overall, diurnal, meals
Automated insulin
delivery
Based on total daily insulin dose last
2-6 days













Glucose target 670G: Target 6.7mmol/L
non-customisable.
780G: Customisable target of 5.5,
6.1, or 6.7mmol/L.
Target range 6.2 – 8.9mmol/L.




adjustable in 0.1mmol/L increments.
Adjustable settings
in CL
ICR, active insulin time, glucose target Basal rates, ICR, ISF, target range ICR, glucose target
Non-adjustable in
CL
Basal rates, ISF (automatically
calculated and adapted)
Active insulin time (set at 5 hours) Basal rates, active insulin time, ISF (all
automatically calculated and adapted)
Exercise mode 670G: No
780G: Yes
Yes Yes






Sick day rules —————————————–Recommended to revert to open loop for illness and/or ketones—————————————-
Automatically reverts
to open loop if…
Prolonged hyperglycemia (670G
only), max/min insulin delivery, loss of
CGM data, sensor integrity concerns,
lack of calibrations.








Meal bolus ———————————————-Pre-meal bolusing recommended for optimal outcomes———————————————
Late bolusing can lead to insulin stacking and hypoglycaemia as CL insulin delivery increases in response to rising glucose
Hypo treatment ——————Consider treating hypoglycaemia with fewer carbohydrates depending on recent insulin delivery——————-
System optimisation • System requires finger pricks for
HCL functioning
• Use of temp target will turn off
automated corrections (780G only)
• Extended bolus / combo bolus
function not available in CL
• Set sleep activity schedule overnight for
tighter target
• Adjust doses for individuals with shorter
active insulin time
• Extended bolus possible in CL, max 2
hours
• Use exercise mode “Ease-Off”
following hypoglycaemia
• Use “Boost” mode during periods of
high glucose
• Extended bolus / combo bolus
function not available in CL







Type of sensor Guardian 3 Dexcom G6 Dexcom G6
Calibrations 670G: 4–6 per day
780G: 1–2 per day
Rarely required (factory calibrated) Rarely required (factory calibrated)





Remote monitoring No (App in development for 780G) Yes – Dexcom follow Yes – Text Alert (Dexcom Follow
planned for 2021)
Upload/Data sharing Manual downloading Automated cloud storage for Dexcom
data; manual downloading for pump
Automated cloud storage to Diasend
(Clarity in 2021)
Remote bolusing No No Yes
MPC, model predictive control; CGM, continuous glucose monitor; TDD, total daily insulin dose; ICR, insulin-to-carbohydrate ratio; ISF, insulin-sensitivity factor; CL, closed-loop.
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CHILDREN
There is significantly more evidence of closed-loop safety and
efficacy in school-aged children, compared to those below the
age of 7 years. Studies of longer duration in larger cohorts show
significant improvements in glycaemic control (26, 30), with no
difference in time in hypoglycaemia (Table 1).
Despite their young age, school-aged children often
independently manage their diabetes to a significant extent
(10). This is in part due to a high turnover of caregiving adults,
whose diabetes management knowledge is often minimal (44).
This leads parents and children to tolerate higher glucose
levels to avoid hypoglycaemia (10, 45), and may limit children’s
ability to participate in certain activities or events without
parental supervision.
Closed-loop systems address this issue in two ways. The
automation of insulin delivery in response to real-time sensor
glucose levels reduces the need for user input, and events
such as post-prandial hyperglycaemia or exercise-induced
hypoglycaemia may be prevented or attenuated by the closed-
loop system itself. This system-innate responsiveness has the
potential to give children more freedom in their activities
by increasing parents’ confidence in the child’s safety. In
a qualitative study interviewing parents of children using
a closed-loop system, they reported being more willing to
allow their child to participate in activities such as school
trips or sleepovers than before (21). Secondly, the remote
monitoring capabilities of some closed-loop systems give
reassurance to parents and children, by allowing parents to
adopt a watchful waiting approach, and to intervene and
support their child’s decision making if required (46). Both
parents and children reported closed-loop insulin delivery
improving their quality of life and reducing diabetesmanagement
burden (21, 38).
While clinical trial evidence shows significant benefits
with closed-loop insulin delivery in terms of glycaemic
control, parents noted the importance of trusting the closed-
loop system for optimum benefit (21). They noted that
an initial adjustment period was required, during which
they realized that taking action to address low or high
glucose levels could be counter-productive to the system’s
ability to manage glucose levels (21). Additional education
around minimizing interventions when using closed-loop
insulin delivery could be beneficial when commencing
this therapy.
Similar to younger children, real-world closed-loop data
is limited. All commercially available closed-loop systems,
apart from the 670G HCL system, were only licensed for
children in the last 12–18 months. A prospective observational
study of people aged 9–61 years using the 670G HCL
system for 1 year found that closed-loop use declined
significantly over time with a high proportion of closed-
loop discontinuation (47). Children and adolescents were
more likely to discontinue closed-loop. The main reasons for
discontinuation were frequent sensor calibration requirements
and a high number of closed-loop exits (47). Another prospective
observational study of youth aged 2–25 years using the
670G HCL system showed similar results, with a steady
decline of closed-loop use over time (48). Newer generation
systems, such as Control IQ and CamAPS FX, using a
factory-calibrated sensor alleviate a key reason for closed-loop
discontinuation. While the 780G AHCL system still requires
sensor calibration, clinical trials show a significant reduction
in closed-loop exits (24), suggesting improved usability in this
newer iteration.
YOUNG PEOPLE
HbA1c levels are highest in young people aged 13–
17 years (5). Diabetes self-management is particularly
challenging in this age group due to a variety of factors,
including peer group influences, importance of body
image, less parental oversight, greater risk-taking, and
fear of hypoglycaemia, leading to higher levels of diabetes
distress (49, 50). Closed-loop insulin delivery offers a
novel way to address these issues, although important
considerations remain with regards to choice of system for
individual users.
Clinical studies have shown that closed-loop insulin delivery
significantly improves glycaemic control in this age-group
(25, 51), including in those with sub-optimal glycaemic
control (30), and that improvements are sustained over
time (27, 52). Importantly, qualitative studies of young
people using closed-loop and their parents have reported
significant improvements in quality of life and reduced diabetes
management burden (21, 46, 49, 50).
Fitting in with peers and taking part in normal activities
is very important to young people (50), which can lead
them to neglect diabetes self-management tasks such as
finger prick blood glucose checks and pre-meal bolusing (53).
Glucose sensors reduce burden and allow young people to
discreetly check glucose levels, as well as allowing glucose-
responsive insulin delivery in closed-loop. While sensors
requiring calibration can be a significant factor in low closed-
loop usage (38, 48, 54), several systems now use factory-
calibrated glucose sensors, with high sensor wear reported
in clinical trials (52) and reduced device-burden reported in
qualitative studies (49). In a qualitative study of young people
using closed-loop from onset of diabetes, participants reported
that the closed-loop system had helped them continue to
lead normal lives despite having diabetes (49) by alleviating
the need for disruptive finger pricking and automatically
adjusting insulin delivery in response to high or low glucose
levels (50, 55).
Current closed-loop insulin delivery systems are all hybrid
systems, which require user-initiated prandial boluses for
optimal efficacy. However, studies have shown that systems have
the ability to cope with missed boluses, while still providing
improvements in short-term glycaemic control without an
increase in hypoglycaemia (53). Data from a recent 6-month
closed-loop study using Control IQ in young people aged
14–24 years showed sustained glycaemic improvements
(27), suggesting that closed-loop remains efficacious in
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a group where there is higher likelihood of sub-optimal
compliance (53).
Common barriers to closed-loop insulin delivery in this age
group are device burden and alarm frequency (49). Young
people preferentially wear devices in non-visible locations (21)
and at times avoid activities where devices may be visible
to others, such as swimming (49). A system with remote
data viewing and bolusing capability via a mobile phone was
positively received by young people, as this offered maximum
discretion in peer environments (50) while enabling them
to make management decisions (21, 49). Audible alarms can
negatively impact quality of life, and in a qualitative study
of closed-loop in this age group parents reported some
young people opting to disconnect from the system when
socializing with peers to limit alarms sounding in public (50).
Most systems now feature personalisable alarm settings and
healthcare providers should support young people in choosing
settings that minimize interruptions while providing an adequate
safety net.
Real-world data of the first commercially available hybrid
closed-loop system, the 670G HCL system, showed high
rates of closed-loop discontinuation, due to frequent sensor
calibration requirements and a high number of closed-loop
exits (47, 48). As described above, newer generation systems
have shown much higher closed-loop use and fewer closed-
loop exits in clinical trials (24, 27). A recently published real-
world study assessed glycaemic control and quality of life by
administering questionnaires to more than 1,000 Control-IQ
users aged 14 years and over (21). Users reported a positive
impact on their quality of life and sleep quality over a 2-
month period after starting closed-loop therapy. Minimizing
device and alarm burden and enabling easy and discreet user
interaction, while maintaining glycaemic benefits should be the
main goals of further closed-loop system developments in this
age group.
FUTURE RESEARCH
Across all pediatric age groups device burden and connectivity
problems remain an issue with regards to closed-loop insulin
delivery (49, 50, 55). System-integration with factory-calibrated
sensors is paramount to ensure high and sustained closed-loop
usage. Connectivity issues resulting in closed-loop exits need
to be improved, for example by increasing allowable distance
between devices or integrating the algorithm with smart devices,
such as watches. Remote data viewing and bolusing capabilities
are highly valued by parents of young children, as this minimizes
disturbance during sleep or play, and also by young people,
where it allows discreet interaction with the closed-loop system,
and this should become standard to all commercial closed-
loop systems (21). Furthermore, automatic cloud storage and
data sharing facilitates interaction with healthcare providers
and improves remote consultations, reducing burden (56).
Currently, most systems are limited to one pump and CGM
model, with specific devices having user-dependent pros and
cons. Inter-operable systems, where users can mix and match
devices that suit their individual needs, should be the focus of
future developments.
The majority of systems are not licensed for very young
children, and there is lack of clinical trial evidence with regards
to efficacy and safety over longer periods. Clinical guidance is
required for those whose total daily insulin dose is below the
required threshold for closed-loop operation. Particularly for
young people, new faster insulins could provide an increasingly
realistic pathway to a more fully closed-loop system, where
accurate carbohydrate counting and prandial bolusing is no
longer required. Closed-loop studies in the pediatric age-group
with ultra-rapid acting insulins are required to assess feasibility
and safety.
Due to the novelty of closed-loop insulin delivery technology
there is little real-world evidence to guide clinicians and users.
Longer-term real-world studies are required to assess whether
glycaemic and quality of life benefits are sustained long-term and
what features are most desired by users to improve ease-of-use.
This will inform system reimbursement, facilitating wider access
across the diabetes population. Furthermore, several systems
now incorporate personalisable glucose targets, as well as user-
initiated modes that reduce or intensify insulin delivery. While
users have expressed a wish for more collaboration with closed-
loop systems in qualitative studies (49), safety and efficacy of
these features needs to be evaluated to help optimize their use.
One of the most important issues facing healthcare providers
and the diabetes community is access to closed-loop therapy.
Insurance coverage of closed-loop therapy is currently poorly
established, and the high cost of CGM and insulin pumps is a
significant barrier to uptake for those who cannot afford to self-
fund the technology (57). This may lead to growing disparities
in those from lower socio-economic backgrounds (57). Future
research needs to incorporate robust health economic analysis
and should aim to show long-term cost-effectiveness to aid
reimbursement for closed-loop therapy.
CONCLUSION
Closed-loop insulin delivery improves glycaemic control in
all pediatric age groups, while crucially reducing the high
management burden associated with this chronic disease, thus
improving quality of life for the whole family. Children, young
people, and their families now have a variety of commercially
available closed-loop systems to choose from, with further
systems in development. Future research should focus on
improving systems to further reduce diabetes management
burden and optimize efficacy, ultimately informing system
reimbursement and facilitating wider access across the
diabetes population.
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